Robert F. Kennedy Jr. lost in court. Then he gave himself more power anyway.
On April 15, a federal judge in Washington, D.C., blocked the Health and Human Services secretary from dissolving the Advisory Committee on Immunization Practices, the expert panel that has guided U.S. vaccine policy for more than six decades. The ruling was a victory for public health advocates and the state attorneys general who brought the challenge. It was supposed to preserve the status quo. Instead, it appears to have accelerated Kennedy’s campaign to reshape how the federal government makes decisions about vaccines — by rewriting the committee’s charter and concentrating authority in his own hands.
According to Ars Technica, Kennedy responded to the court setback by issuing a new charter for ACIP that fundamentally alters the committee’s composition, independence, and influence. The revised charter strips the panel of much of its traditional authority and inserts the HHS secretary — Kennedy himself — as the ultimate decision-maker on vaccine recommendations. Where ACIP’s guidance once carried near-automatic weight with the Centers for Disease Control and Prevention, the new framework makes its recommendations merely advisory in the most diminished sense of the word.
This matters enormously. Not just for immunologists and pediatricians, but for every American whose health insurance covers vaccines, every parent consulting the CDC’s childhood immunization schedule, and every pharmacist deciding what to stock on the shelf.
ACIP isn’t a household name, but its fingerprints are on virtually every vaccination decision made in the United States. Created in 1964, the committee comprises fifteen voting members — physicians, immunologists, epidemiologists, and public health experts — who review clinical trial data, post-market surveillance, and cost-effectiveness analyses before recommending which vaccines Americans should receive and when. Those recommendations don’t just inform clinical practice. They trigger a regulatory cascade: once the CDC director formally adopts an ACIP recommendation, the Affordable Care Act requires most private insurers to cover the vaccine with no out-of-pocket cost. For children enrolled in the Vaccines for Children program, ACIP recommendations determine which shots are provided free of charge to roughly half the kids in America.
So when Kennedy rewrites ACIP’s charter, he isn’t shuffling bureaucratic deck chairs. He’s reaching into the mechanism that connects scientific evidence to insurance coverage to actual needles in actual arms.
The new charter, as reported by Ars Technica, makes several significant changes. First, it reduces the number of voting members and alters the qualifications for appointment, opening the door to members who lack traditional expertise in vaccinology or infectious disease. Second, it removes or weakens conflict-of-interest provisions that previously barred members with financial ties to vaccine manufacturers from voting on related products. Third — and most critically — it stipulates that ACIP’s recommendations no longer carry binding implications for CDC policy. The HHS secretary reserves the right to accept, modify, or reject any recommendation the panel makes.
That last provision is the one that should keep public health officials up at night.
Under the previous framework, the CDC director almost invariably adopted ACIP’s recommendations. The process was designed to insulate vaccine policy from political interference, creating a buffer of scientific peer review between elected officials and clinical guidelines. Kennedy’s new charter demolishes that buffer. It transforms ACIP from a body whose expert consensus shaped national policy into a body whose expert opinions can be overridden by a single political appointee — one who has spent decades publicly questioning vaccine safety and efficacy.
Kennedy has long maintained that he is not “anti-vaccine” but “pro-safety.” His critics, including the vast majority of the immunology and pediatrics community, disagree sharply. Before joining the Trump administration, Kennedy founded Children’s Health Defense, an organization that the New York Times and other outlets have described as one of the most prominent sources of vaccine misinformation in the country. He has repeatedly suggested links between childhood vaccines and autism — a claim that has been exhaustively studied and refuted by researchers worldwide. He has questioned the safety of the measles, mumps, and rubella vaccine. He has cast doubt on the science behind COVID-19 immunizations.
Now he holds the pen that writes the rules for how America evaluates all of them.
The court ruling that preceded this charter rewrite came from Judge James Boasberg of the U.S. District Court for the District of Columbia. A coalition of state attorneys general, led by several Democratic AGs, had filed suit arguing that Kennedy lacked the statutory authority to unilaterally dissolve ACIP, which was established by Congress. Boasberg agreed, issuing a preliminary injunction that barred HHS from disbanding the committee. The judge found that the plaintiffs were likely to succeed on the merits of their claim and that dissolving ACIP would cause irreparable harm to public health.
Kennedy couldn’t kill the committee. So he defanged it.
Legal experts quoted by Ars Technica noted that the charter rewrite may represent an attempt to achieve through administrative maneuvering what the court prevented through dissolution. “The committee exists in name, but its function has been gutted,” one health law professor observed. Whether this end-run survives its own legal challenge remains an open question. The same attorneys general who blocked ACIP’s dissolution are almost certain to argue that rewriting the charter to nullify the committee’s practical authority violates the spirit, if not the letter, of the court’s injunction.
But litigation takes time. And in the interim, vaccine policy drifts.
The practical consequences are already materializing. Without a functioning ACIP that can issue recommendations with real policy weight, new vaccines face an uncertain path to coverage. Consider the pipeline: updated COVID-19 boosters, next-generation RSV vaccines for infants, potential new formulations for influenza. Each of these products would normally go through ACIP review, receive a recommendation, and then flow into the insurance coverage machinery. If Kennedy can override or simply ignore ACIP’s guidance, the entire system stalls — or worse, becomes subject to the ideological preferences of a single official.
Vaccine manufacturers are watching closely. Companies like Pfizer, Moderna, Merck, and GSK have built business models around the predictability of the ACIP process. An ACIP recommendation is, in practical terms, a market-access event. It signals to insurers, providers, and public health departments that a vaccine has cleared the highest bar of independent scientific review. Remove that signal — or make it unreliable — and the commercial calculus for vaccine development changes dramatically. Why invest billions in clinical trials for a product whose market access depends on the whims of a political appointee?
This isn’t hypothetical. Industry sources speaking to reporters at Reuters in recent weeks have described a chilling effect on vaccine R&D investment decisions. “The ACIP process was the gold standard,” one pharmaceutical executive said. “If that’s gone, we need to rethink our entire development strategy for the U.S. market.”
The implications extend beyond American borders. ACIP recommendations have historically influenced vaccine policy in dozens of countries that look to the United States as a reference point. The World Health Organization’s Strategic Advisory Group of Experts on Immunization, known as SAGE, frequently cites ACIP analyses in its own deliberations. A weakened or politicized ACIP doesn’t just affect Americans — it erodes a pillar of the global immunization architecture.
And then there’s the question of what happens at the state level. Vaccine mandates for school entry are set by individual states, but those mandates have traditionally tracked ACIP recommendations closely. If ACIP’s recommendations become unreliable or politically tainted, state health departments will face pressure to establish their own independent review processes — a costly and redundant undertaking that few state budgets can absorb. Some states may simply stop updating their requirements, leaving children vulnerable to preventable diseases. Others may go in the opposite direction, adopting more permissive exemption policies that further erode herd immunity.
The timing couldn’t be worse. Measles cases in the United States have surged in 2025 and into 2026, driven by declining vaccination rates in pockets of the country where vaccine skepticism has taken hold. The CDC reported earlier this year that MMR vaccination coverage among kindergartners dropped below 90% nationally for the first time in decades — well below the 95% threshold needed to prevent sustained measles transmission. Public health officials have warned that the erosion of ACIP’s authority could accelerate this trend by sending a signal that the government’s own experts can’t be trusted.
Kennedy’s allies see it differently. Conservative health policy advocates have argued that ACIP was too insular, too deferential to pharmaceutical companies, and too resistant to dissenting viewpoints. They point to the committee’s conflict-of-interest waivers — which occasionally allowed members with industry ties to participate in deliberations — as evidence that the panel was captured by the very companies it was supposed to evaluate objectively. The charter rewrite, in this telling, is a corrective. A restoration of democratic accountability over an unelected body that wielded enormous power with minimal oversight.
There’s a kernel of truth in the critique. ACIP’s conflict-of-interest policies were imperfect, and reasonable people can disagree about how aggressively financial ties should be policed. But the solution Kennedy has chosen — concentrating final authority in the HHS secretary — doesn’t solve the conflict-of-interest problem. It replaces one set of potential conflicts with another, far more dangerous one: the conflict between evidence-based medicine and the political commitments of an appointee who built his career on challenging the scientific consensus about vaccines.
Former ACIP members have been unusually vocal in their criticism. Dr. Grace Lee, a Stanford pediatrician who chaired the committee during the COVID-19 vaccine rollout, told reporters that the charter changes “undermine the scientific integrity that has made ACIP a trusted institution for sixty years.” Other former members have described the new charter as “unrecognizable” compared to the framework under which they served.
The legal battle is far from over. Attorneys general in several states have signaled they will challenge the charter rewrite, arguing it constitutes a constructive dissolution of ACIP in violation of Judge Boasberg’s injunction. Health law scholars are divided on whether that argument will succeed. The injunction specifically prohibited HHS from disbanding the committee — it didn’t explicitly address the scope of the secretary’s authority to modify the committee’s charter or operating procedures. Kennedy’s lawyers will almost certainly argue that the charter rewrite is a lawful exercise of executive discretion, well within the secretary’s statutory authority to manage advisory committees under the Federal Advisory Committee Act.
That argument isn’t frivolous. FACA gives agency heads considerable latitude in structuring advisory committees, including the authority to define their scope, membership, and operating procedures. But it also requires that advisory committees be “fairly balanced in terms of the points of view represented” and that their advice not be “inappropriately influenced” by the appointing authority. Whether Kennedy’s charter rewrite crosses those lines will likely be the central question in the next round of litigation.
Meanwhile, the CDC itself is in a state of institutional uncertainty. Director-level positions remain unfilled or occupied by acting officials. Morale among career scientists has plummeted, according to internal surveys and reporting by The Washington Post. The agency’s ability to conduct independent scientific review — always dependent on political support from HHS leadership — is more constrained than at any point in its modern history.
What’s unfolding is not simply a policy dispute. It’s a structural transformation of how the United States makes decisions about one of the most consequential interventions in the history of medicine. Vaccination has prevented an estimated 154 million deaths worldwide over the past fifty years, according to WHO data. The system that supports vaccination in America — the clinical trials, the expert review, the insurance mandates, the public trust — is intricate and interdependent. Pull one thread, and the whole thing frays.
Kennedy is pulling hard.
The question now is whether the courts, Congress, or the states can hold the fabric together — or whether the country’s vaccine infrastructure will be remade in the image of a man who has spent his career questioning its foundations. For the millions of Americans who depend on that infrastructure, the answer can’t come soon enough.
WebProNews is an iEntry Publication